US FDA approves Bristol-Myers immunotherapy for lung cancer

March 4 (Reuters) - U.S. health regulators on Wednesday approved Bristol-Myers Squibb Co's drug, Opdivo, which helps the immune system fight cancer, to treat squamous non-small cell lung cancer once the disease has progressed following platinum-based chemotherapy.